<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02000401</url>
  </required_header>
  <id_info>
    <org_study_id>0703-2012-SPRIX</org_study_id>
    <nct_id>NCT02000401</nct_id>
  </id_info>
  <brief_title>Intranasal Ketorolac Tromethamine (Sprix) for Acute Pain of Interstitial Cystitis Flare of Pain</brief_title>
  <official_title>To Evaluate the Efficacy, Tolerability, and Safety of Intranasal Ketorolac Tromethamine (Sprix) as an Option for Acute (up to 5 Days) Pain Management Adult Interstitial Cystitis Patients Experiencing a Flare of Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Citrus Valley Medical Research, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Citrus Valley Medical Research, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intranasal Ketorolac tromethamine has a potential role as a short term pain management tool
      for Interstitial Cystitis without the risk and undesirable effects of narcotics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Scores on the Visual Analog Scale</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Interstitial Cystitis</condition>
  <arm_group>
    <arm_group_label>Ketorolac Tromethamine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ketorolac Tromethamine one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs. as needed for pain with a maximum daily dose of 126 mg. The treatment may be continued for up to 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac Tromethamine</intervention_name>
    <arm_group_label>Ketorolac Tromethamine</arm_group_label>
    <other_name>SPRIX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female Subject must be between the age eighteen (18) years and sixty four (64)

          2. Subject must weigh 110lbs (50kg) or greater

          3. Willing and able to provide an informed consent

          4. Diagnosed with Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)

          5. Symptoms of IC/PBS that are moderate to severe (intermittent or chronic) for ≥ three
             (3) months

          6. A cystoscopic examination under anesthesia with hydro-distention and photo
             documentation will have been performed at time of diagnosis with IC. Bladder biopsies
             will have been performed only if carcinoma is suspected. (see exclusion # 5.2.25 -
             hydrodistention must be performed greater than four (4) weeks prior to baseline visit)
             Note: at investigator discretion subject may included with only operative report

          7. At screening subject must have a score ≥ four (4) out of ten (10) On Visual Analogue
             Pain Scale (VAS Pain Scale)

          8. Subject must have a score on the O'Leary/Sant scale of at least a five (5) on the
             symptom index at screening

          9. Voids greater than eight (8) in a twenty four (24) hour period

         10. Nocturia of at least one (1) time during sleeping period

         11. Subject of child-bearing potential must test negative for pregnancy prior to treatment
             or provide documentation for having undergone the following: hysterectomy or tubal
             ligation. Subjects who are physiologically capable of becoming pregnant must
             voluntarily sign a pregnancy waiver included within the informed consent and agree not
             to become pregnant for the duration of the study and for thirty (30) days following
             the completion of study. If a subject becomes pregnant during the course of this
             study, the subject will inform the Principal Investigator within one (1) working day
             of learning of the pregnancy

        Exclusion Criteria:

          1. Current treatment with or known allergy or sensitivity to all forms of ketorolac
             tromethamine, aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs) or
             Ethylenediaminetetraacetic acid (EDTA) NOTE: if at time of signing consent a subject
             is receiving a non-steroidal inflammatory drug they may washout for seven days prior
             to completing the screening visit

          2. Subject is currently receiving or having had prior IC/PBS focused therapy on less than
             three (3) months stable doses. i.e. oral Pentosan Polysulfate(PPS) (Elmiron®),
             Amitriptyline (Elavil®), oxychlorosene (Clorpactin®), dimethyl sulfoxide (RIMSO 50™),
             heparin or antihistamine NOTE: Antihistamine is allowable as added treatment during
             course of study if for treatment of diagnosed nasal/seasonal/environmental allergy
             (i.e treatment other than IC) , If a subject is receiving intravesical instillations
             of any kind at least a two day washout must be adhered to before screening is
             performed. The subject must abstain from any intravesical instillation during the
             study.

          3. Current use of TENS (Transcutaneous Electrical Nerve Stimulation) or Interstim unit

          4. Clinically significant urinary tract infection (UTI) NOTE: dipstick urinalysis is done
             at screening urine culture will be performed if indicated by results of dipstick
             urinalysis at screening

          5. As needed Use of narcotics/opiate within one (1) week prior to the screening visit and
             entire study participation by self-reporting (Note: once subject has qualified they
             will be given the option of rescue medication for pain not relieved by the study
             medication)

          6. Use of illegal drugs by self-reporting

          7. History of drug or alcohol abuse within five (5) years of screening visit

          8. History of suicide attempt or suicidal thoughts by self-reporting within five (5)
             years of screening visit

          9. Any active co-morbid pelvic diagnosis (i.e. endometriosis, Irritable Bowel Syndrome,
             etc.) for which the subject is unable to distinguish between IC/PBS pain and pain from
             any other condition as determined by the investigator

         10. A diagnosis of a severe neuro-psychiatric disease

         11. Subject demonstrates an absence of nocturia

         12. Subject's frequency of urination is equal to or less than eight (8) times in a twenty
             four (24) hour period.

         13. Subject's symptoms relieved by antimicrobials, urinary antiseptics, anticholinergics,
             or antispasmodics.

         14. Subject has recurrent bladder or lower urethral calculi (recurrent is defined as &gt; to
             3 times in a 12 month period)

         15. Subject has active genital herpes with a (3) three month period of the screening visit

         16. Subject has uterine, cervical, vaginal, or urethral cancer

         17. Subject has been administered cyclophosphamide or any agent that causes chemical
             cystitis

         18. Subject has tubercular cystitis

         19. Subject has radiation cystitis

         20. Subject has benign or malignant bladder tumor

         21. Subject has a positive pathologic vaginal culture within three (3) months of the
             screening visit

         22. Subject has evidence of vesicle ureteral reflux or urethral diverticula

         23. Subject has neurogenic bladder dysfunction

         24. Subject has a prior urinary diversion

         25. Subject who is currently receiving investigational drug(s) or participated in a
             clinical trial involving investigational drug(s) within thirty (30) day of the
             screening visit

         26. Subject who is pregnant or lactating

         27. Subject with history of hydro-distention within four (4) weeks of baseline visit

         28. Subject with history of clinically significant cardiovascular disease such as:
             (chronic stable angina being currently treated with long acting nitrates, chronic
             stable angina require treatment with short acting nitrates with 90 days of visit 1,
             angina occurring during sexual intercourse in the last six months, unstable angina
             within six months of visit 1

         29. Resting, sitting blood pressure (BP) &gt; 160mm Hg in systolic pressure or &gt; 100mm Hg is
             diastolic pressure at screening. If a patient is found to have untreated significant
             hypertension at screening and antihypertensive treatment is initiated, assessment for
             study eligibility should be deferred until BP and antihypertensive medication have
             been stable for at least one month. For patients with previously diagnosed
             hypertension, antihypertensive medications must be stable for at least one month prior
             to screening.

         30. Subject over sixty four (64) years of age

         31. Subject who weighs less than 110lbs (50kg)

         32. Subject with history of any clinically significant blood chemistry, renal function or
             liver abnormality defined as + two (2X) normal values

         33. Subject who has history of a bleeding problem or low platelet count

         34. Known or suspected cerebrovascular bleeding, hemorrhagic diathesis or incomplete
             hemostasis, and those at high risk of bleeding, have history of a bleeding problem or
             low platelet count or coagulation disorder or are on therapy that affects homeostasis

         35. Active peptic ulcer disease, recent GI bleeding or perforation, or a history of peptic
             ulcers or GI bleeding

         36. History of asthma, urticaria or other allergic-type reaction after taking aspirin or
             other non- steroidal inflammatory drugs (NASIDs)

         37. Subject who has history of swelling of face, mouth, tongue, lips, gums, neck, or
             throat (angioedema) or with cardiac decompensation or similar conditions

         38. Major surgery scheduled within 3 weeks or screening and for entire participation of
             study

         39. Current exfoliative dermatitis, Stevens-Johnson syndrome or toxic epidermal necrolysis

         40. Any condition in the opinion of the investigator that makes the subject unsuitable for
             study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward L Davis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Citrus Valley Medical Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Citrus Valley Medical Research, Inc</name>
      <address>
        <city>Glendora</city>
        <state>California</state>
        <zip>91741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>December 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2013</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

